Cargando…

ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation

Acquired or de novo resistance to trastuzumab remains a barrier to patient survival and mechanisms underlying this still remain unclear. Using stable isotope labelling by amino acids in cell culture (SILAC)-based quantitative proteomics to compare proteome profiles between trastuzumab sensitive/resi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nunes, Joao, Zhang, Hua, Angelopoulos, Nicos, Chhetri, Jyoti, Osipo, Clodia, Grothey, Arnhild, Stebbing, Justin, Giamas, Georgios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053674/ https://www.ncbi.nlm.nih.gov/pubmed/27050377 http://dx.doi.org/10.18632/oncotarget.8504

Ejemplares similares

Proteomic profile of KSR1-regulated signalling in response to genotoxic agents in breast cancer
por: Zhang, Hua, et al.
Publicado: (2015)

Characterization of the Tyrosine Kinase-Regulated Proteome in Breast Cancer by Combined use of RNA interference (RNAi) and Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) Quantitative Proteomics
por: Stebbing, Justin, et al.
Publicado: (2015)

Trastuzumab Resistance: Role for Notch Signaling
por: Mehta, Kinnari, et al.
Publicado: (2009)

Proteome-wide dataset supporting functional study of tyrosine kinases in breast cancer
por: Angelopoulos, Nicos, et al.
Publicado: (2016)

Cancer stem cells and HER2 positive breast cancer: The story so far
por: Shah, Deep, et al.
Publicado: (2016)

Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer
por: Baker, Andrew T., et al.
Publicado: (2014)

Targeting Breast Cancer Stem Cells Using Naturally Occurring Phytoestrogens
por: Nguyen, Mai, et al.
Publicado: (2022)

Notch versus the proteasome: what is the target of γ-secretase inhibitor-I?
por: Clementz, Anthony G, et al.
Publicado: (2009)

Lemur tyrosine kinase-3 (LMTK3) in cancer and evolution
por: Stebbing, Justin, et al.
Publicado: (2011)

The many-faced KSR1: a tumor suppressor in breast cancer
por: Zhang, Hua, et al.
Publicado: (2015)

Notch Signaling in Breast Cancer: A Role in Drug Resistance
por: BeLow, McKenna, et al.
Publicado: (2020)

Gamma secretase inhibitors of Notch signaling
por: Olsauskas-Kuprys, Roma, et al.
Publicado: (2013)

Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
por: Rani, Aradhana, et al.
Publicado: (2019)

The Effect of Cold Ischemia Time and/or Formalin Fixation on Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Results in Breast Carcinoma
por: Pekmezci, Melike, et al.
Publicado: (2012)

DAXX-inducing phytoestrogens inhibit ER+ tumor initiating cells and delay tumor development
por: Peiffer, Daniel S., et al.
Publicado: (2020)

NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications
por: Clementz, Anthony G, et al.
Publicado: (2011)

Strategic Trastuzumab Mediated Crosslinking Driving Concomitant HER2 and HER3 Endocytosis and Degradation in Breast Cancer
por: Wymant, Jennifer Mary, et al.
Publicado: (2020)

Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency
por: Huemer, Martina, et al.
Publicado: (2016)

ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3
por: Ebbing, Eva A., et al.
Publicado: (2016)

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
por: Xing, Fei, et al.
Publicado: (2023)

A Prediction Model Using Alternative Splicing Events and the Immune Microenvironment Signature in Lung Adenocarcinoma
por: Zhu, Liping, et al.
Publicado: (2021)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

YES1 amplification confers trastuzumab–emtansine (T-DM1) resistance in HER2-positive cancer
por: Wang, Lei, et al.
Publicado: (2020)

Reorienting the Fab Domains of Trastuzumab Results in Potent HER2 Activators
por: Scheer, Justin M., et al.
Publicado: (2012)

C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells
por: Li, Wei, et al.
Publicado: (2018)

Correction to: LMTK3 inhibition affects microtubule Stability
por: Cilibrasi, Chiara, et al.
Publicado: (2021)

LMTK3 inhibition affects microtubule stability
por: Cilibrasi, Chiara, et al.
Publicado: (2021)

A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers
por: Peng, Ling, et al.
Publicado: (2021)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
por: Rudkouskaya, Alena, et al.
Publicado: (2020)

Enigma Prevents Cbl-c-Mediated Ubiquitination and Degradation of RETMEN2A
por: Kales, Stephen C., et al.
Publicado: (2014)

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
por: Yoshino, Takayuki, et al.
Publicado: (2023)

STAT3 activation confers trastuzumab‐emtansine (T‐DM1) resistance in HER2‐positive breast cancer
por: Wang, Lei, et al.
Publicado: (2018)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer
por: Han, Mingli, et al.
Publicado: (2020)

LMTK3 confers chemo-resistance in breast cancer
por: Stebbing, Justin, et al.
Publicado: (2018)

A novel CBL-B(flox/flox) mouse model allows tissue-selective fully conditional CBL/CBL-B double-knockout: CD4-Cre mediated CBL/CBL-B deletion occurs in both T-cells and hematopoietic stem cells
por: Goetz, Benjamin, et al.
Publicado: (2016)

miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer
por: Cabello, Paula, et al.
Publicado: (2023)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_354aik8t2etf9b6btgfnetg1s9